Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fortreon is a defunct trademark filed by Bayer Aktiengesellschaft in November 2000, intended for a veterinary endectocide product for domestic small animals. Endectocides are antiparasitic agents effective against both endoparasites (such as nematodes) and ectoparasites (such as fleas and ticks). The trademark application was published in 2001 but subsequently abandoned in January 2002. No specific active ingredients, biological targets, or clinical trial data have been publicly associated with the name, indicating that the product likely did not proceed into advanced development or commercialization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fortreon.